Follow WOWNEWS 24x7 on:
Par Drugs and Chemicals Ltd, an active pharmaceutical ingredient (API) manufacturer, is under heightened regulatory examination following a series of directives and actions by the Securities and Exchange Board of India (SEBI) and the National Stock Exchange (NSE). The regulator has intervened to ensure fair valuation of business undertakings related to a proposed slump sale, restraining deal execution and issuing an ex-parte interim order against the company and associated entities.
Key Highlights Of SEBI and NSE Regulatory Actions
SEBI has restrained Par Drugs and Chemicals Ltd from executing the Business Transfer Agreement (BTA) dated February 14, 2025, involving the slump sale of its core business undertaking to Phal-Jig Fine Chemicals Pvt Ltd, a promoter group entity.
The regulator cited prima facie irregularities concerning valuation fairness, shareholder communication, and the voting process related to the proposed slump sale valued at Rs 95 crore.
SEBI directed NSE to appoint an independent registered valuer tasked with re-examining the business undertaking’s fair market value using recognized valuation standards and methodologies.
The valuer must submit the valuation report within three months, after which NSE is required to seek a fairness opinion from a merchant banker within one month of receiving the valuation.
Both the valuation report and fairness opinion, along with NSE’s recommendation, are mandated to be submitted within 15 days of receipt of the fairness opinion for SEBI’s further review.
SEBI issued an ex-parte interim order restraining Par Drugs and associated promoter group entity from further dealings in relation to the transfer agreement to prevent potentially irreversible asset disposals.
The regulator highlighted concerns about significant erosion in market capitalization, which has dropped nearly 70 percent since the slump sale announcement at the current valuation.
SEBI’s whole-time member emphasized the urgent need for intervention to safeguard public shareholders’ interests against potentially detrimental transactions.
The NSE has also been ordered to appoint an independent valuer to ensure objective re-assessment of the business, reinforcing regulatory oversight.
Par Drugs’ management and all signatories to the BTA have been directed to refrain from undertaking any transaction that may lead to disposal of assets until further directions are provided by SEBI.
Background And Regulatory Context
The proposed slump sale involves transfer of significant business units from Par Drugs to a related promoter entity, raising red flags about valuation accuracy, transparency, and minority shareholder protection. SEBI’s actions reflect its mandate to maintain fair market conduct and protect shareholder interests from transactions perceived as prejudicial or non-compliant with disclosure norms.
Implications For Par Drugs And Market Participants
The regulatory restraint delays Par Drugs’ proposed business reorganization, impacting strategic plans and possibly affecting financial outcomes.
Share prices have already reflected volatility, influenced by regulatory uncertainty and prevailing concerns over corporate governance.
This intervention underlines SEBI’s proactive regulatory environment addressing conflict-of-interest and valuation irregularities in related-party transactions.
Market participants will closely watch subsequent valuation reports, fairness opinions, and NSE’s recommendations for clarity on fair transaction pricing.
Potential re-negotiations or revised frameworks may emerge based on regulator feedback and market reactions.
Understanding SEBI’s Ex-Parte Interim Order Powers
SEBI exercises ex-parte interim orders under provisions allowing urgent action to prevent irreversible damage to stakeholders and markets. Such orders require demonstrable prima facie cases, balance of convenience, and potential for irreparable injury if not imposed. These protective measures uphold investor confidence and market integrity during ongoing investigations.
Next Steps And Outlook
Par Drugs and Chemicals Ltd is expected to comply with SEBI directives, submitting required documents within stipulated timelines. The regulator’s thorough examination will set the tone for resolution pathways, whether through revised transactions, settlements, or further enforcement actions. Investors and analysts will monitor developments impacting the company’s valuation, governance practices, and strategic direction.
In essence, SEBI and NSE’s interventions in Par Drugs and Chemicals Ltd emphasize stringent oversight on related-party transactions and fair valuation practices. This ongoing regulatory scrutiny protects minority shareholders and underscores the importance of transparent processes in corporate restructuring within India’s capital markets.
Sources: Economic Times, Moneycontrol, Free Press Journal, SEBI Orders, NSE Filings
Follow WOWNEWS 24x7 on:
Copyright 2024 WOWNEWS 24x7. All rights reserved. The WOWNEWS 24x7 is not responsible for the content of external sites. Read about our approach to external linking.
Powered By Just Imagine
